Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury

Michael Andrews, Teruhiko Yoshida, Clark M. Henderson, Hannah Pflaum, Ayako McGregor, Joshua A. Lieberman, Ian H. de Boer, Tomas Vaisar, Jonathan Himmelfarb, Bryan Kestenbaum, Stephen M. Hewitt, Briana A. Santo, Brandon Ginley, Pinaki Sarder, Avi Z. Rosenberg, Taichi Murakami, Jeffrey B. Kopp, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle

1 Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 2 Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 3 Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America, 4 Department of Medicine, University of Washington, Seattle, Washington, United States of America, 5 Kidney Research Institute, University of Washington, Seattle, Washington, United States of America, 6 Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America, 7 Department of Pathology and Anatomical Sciences, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America, 8 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America, 9 Department of Nephrology, Ehime Prefectural Central Hospital, Ehime, Japan

Abstract

Background

Genetic variants in apolipoprotein L1 (APOL1), a protein that protects humans from infection with African trypanosomes, explain a substantial proportion of the excess risk of chronic kidney disease affecting individuals with sub-Saharan ancestry. The mechanisms by which risk variants damage kidney cells remain incompletely understood. In preclinical models, APOL1 expressed in podocytes can lead to significant kidney injury. In humans, studies in kidney transplant suggest that the effects of APOL1 variants are predominantly driven by donor genotype. Less attention has been paid to a possible role for circulating APOL1 in kidney injury.

Methods

Using liquid chromatography-tandem mass spectrometry, the concentrations of APOL1 were measured in plasma and urine from participants in the Seattle Kidney Study. Asymmetric flow field-flow fractionation was used to evaluate the size of APOL1-containing lipoprotein particles in plasma. Transgenic mice that express wild-type or risk variant APOL1 from an albumin promoter were treated to cause kidney injury and evaluated for renal disease and pathology.
Results
In human participants, urine concentrations of APOL1 were correlated with plasma concentrations and reduced kidney function. Risk variant APOL1 was enriched in larger particles. In mice, circulating risk variant APOL1-G1 promoted kidney damage and reduced podocyte density without renal expression of APOL1.

Conclusions
These results suggest that plasma APOL1 is dynamic and contributes to the progression of kidney disease in humans, which may have implications for treatment of APOL1-associated kidney disease and for kidney transplantation.

Introduction
In humans, the gene encoding apolipoprotein L1 (APOL1) has two common polymorphic alleles, G1 (rs73885319, rs60910145) and G2 (rs71785313) [1, 2], which are found only in persons of sub-Saharan African ancestry. Carriers of one G1 or G2 polymorphism in APOL1 are protected from African trypanosomiasis, also known as African sleeping sickness [3, 4]. However, persons who are homozygous or compound heterozygous for these alleles have a substantially greater risk of progressive kidney disease, particularly diseases caused by HIV or other precipitants of collapsing focal segmental glomerulosclerosis [1, 2, 5]. Most research directed at mechanisms by which APOL1 might cause kidney function decline has focused on endogenous expression within the kidneys, especially in podocytes [6–11]. Less attention has been paid to circulating plasma APOL1 protein, which may be due to several studies that associate kidney allograft failure to donor genotype [12–14] and to a study showing that plasma levels of risk-variant APOL1 did not associate with renal disease [15]. However, more recent data from a transplant study suggests that recipient genotype, and therefore circulating APOL1, may still be relevant [16].

The non-polymorphic (G0) variant of APOL1 encodes a 44 kDa protein with the sequence LNILNNNK at residues 382–390, which are near the C-terminus [17]. The G1 polymorphism is a missense mutation that leads to the substitution of isoleucine at position 384 with a methionine (LNMLNNNK); a second substitution at position S342 (to glycine) is also present [18]. The G2 polymorphism is a short deletion of residues 388–389 (LNILNNNK) [17]. It has been hypothesized that these sequence variations alter the conformation stability around the leucine zipper motif at the C-terminus and enhance the formation of pores in the cell membrane that lead to cytotoxicity [10, 11, 19–22], although other mechanisms have been proposed, including endoplasmic reticulum stress [23, 24], inflammasome activation [25], pyropotosis [6], protein kinase R activation [26], and mitochondrial dysfunction [27]. Other studies have demonstrated that risk variant APOL1 localizes to different membranes and lipid droplets when expressed in cell models compared to APOL1-G0, suggesting different intracellular biochemical characteristics and behavior [9, 28]. We previously reported that the amount the APOL1 residing on HDL particles was lower in participants with impaired kidney function and hypothesized that APOL1 resides on different particles at different stages of kidney function [29]. This change in extracellular biochemical behavior and the fact that the primary reservoir of APOL1 in the body is circulating in plasma made us revisit the hypothesis that risk
variant APOL1 in plasma could help promote kidney injury and/or disease progression [29–31].

To test the hypotheses that risk variant APOL1 is biochemically different in plasma and contributes to the development and progression of proteinuric kidney diseases like focal segmental glomerulosclerosis and arterionephrosclerosis, we developed assays to quantify APOL1 in plasma, to measure the size of APOL1-containing particles in plasma, and to quantify APOL1 in urine. We also developed a novel mouse model that expresses APOL1-G0, APOL1-G1, or APOL1-G2 in the liver from an albumin promoter and used it to show that circulating APOL1 exacerbates damage to the kidney, particularly the G1 variant. Overall, our studies suggest plasma APOL1, even in the absence of podocyte derived APOL1, could contribute to kidney pathology.

**Materials and methods**

A detailed description of the methods and materials used for these studies is included in [S1 File](#). Brief descriptions are provided here.

**Human samples**

Plasma, urine, and DNA samples were obtained from participants in the Seattle Kidney Study (SKS), an IRB-approved cohort study described previously [32]. Race was self-identified, estimated glomerular filtration rate (eGFR) was calculated from plasma creatinine using the 2021 CKD-EPI equation without a race coefficient included [33], and serum total protein and urine albumin-to-creatinine ratios were determined using an automated clinical chemistry analyzer (Beckman DxC 800, Beckman Coulter, Brea, CA). Amounts of APOL1 in the HDL fraction of plasma were determined previously [29]. In addition to samples from SKS participants, four fresh human plasma samples were acquired from Interstate Blood Bank (Memphis, TN) as quality control materials for size fractionation experiments.

**Quantification of total APOL1 and phenotyping of APOL1 in human plasma**

APOL1 protein was quantified in plasma using trypsin digestion and LC-MS/MS [Waters Acquity I-Class system (Milford, MA) and Waters TQ-S micro, Table A in [S1 File](#)]. The assay was calibrated using external calibrators comprised of pooled human serum diluted into chicken serum [34]. The isoforms of APOL1 present in each plasma sample were also determined by LC-MS/MS by comparing the ratio of each polymorphic APOL1 peptide (LNILNNNYK or LNMLNNNYK) to a non-polymorphic APOL1 peptide (VTEPISAESGEQVER) with empirical minimum cutoffs to detect the presence of peptide vs. absence of peptide, and therefore each haplotype. From these cut-offs, the APOL1 genotype was identified for each participant. While this is a relatively new approach to determining the genotype of the individual, it is similar to other published studies determining the genotype of APOL1 and vitamin D binding protein [34, 35].

**APOL1 genotyping**

The APOL1 G0, G1 (rs73885319), and G2 (rs71785313) alleles were detected by multiplexed qPCR with TaqMan allele-specific primer/probe genotyping assays (ThermoFisher Scientific, Waltham, MA). We used a commercially available set of primers and probes that distinguish the G0 and G1 alleles (ThermoFisher Assay ID: C__98253221_10). To distinguish G0 from G2 alleles, a custom genotyping assay (Assay ID: AN7DPWD) was designed using ThermoFisher’s
custom TaqMan SNP assay design tool following the manufacturer’s instructions. Genotyping in 98 participants was used to cross-validate the phenotyping approach, which demonstrated a 100% agreement between genotype and phenotype.

**Size fractionation, particle size determination, and protein analysis**

Particles in plasma samples were separated using an asymmetric flow field-flow fractionation (AF4) system (AF2000, PostNova Analytics, Salt Lake City, UT) with a UV detector. Forty fractions were collected for each sample. For each fraction, the average hydrodynamic size of particles was determined by dynamic light scattering using a DynaPro plate reader (Wyatt Technologies, Santa Barbara, CA, *Fig A in S1 File*). Proteins in each fraction were then quantified with in-line trypsin digestion and LC-MS/MS (Shimadzu Scientific Instruments/Perfinity Biosciences, West Lafayette, IN). Peptides were monitored using a 6500 QTRAP (AB Sciex, Foster City, CA, USA) in multiple reaction monitoring mode (*Table A in S1 File*). The experimental concentration vs. hydrodynamic size profiles were deconvolved using JMP software (SAS Institute, Cary, North Carolina).

**Quantification of APOL1 in human urine**

Proteins in urine were precipitated with ice-cold acetone/hydrochloric acid. APOL1 was quantified in dried precipitates using trypsin digestion and LC-MS/MS. Heavy-labeled APOL1 internal standard peptide was added prior to digestion.

**Transgenic mice and the triple intervention model**

We generated Alb/APOL1 transgenic mice on the FVB/N background. These mice carry the human APOL1 gene under the control of the murine albumin promoter. We generated three strains: Alb/APOL1-G0, Alb/APOL1-G1 and Alb/APOL1 G2, each of which contains the coding sequence for one of these common APOL1 genetic variants. All mouse experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved in advance by the NIDDK Animal Care and Use Committee (Animal study proposal, K097-KDB-17 & K096-KDB-20). We euthanized mice by cervical dislocation after anesthesia with intraperitoneal 10% tribromethanol (Avertin) injection and after confirming loss of sensation by toe pinching. One Alb/APOL1-G1 mouse died on day 10 of the experimental period and was excluded from analysis (the body weight of this mouse was not different from the other mice). We induced podocyte injury and proteinuria using a triple intervention approach, including administration of interferon-γ, puromycin aminonucleoside, and basic fibroblast growth factor [26]. In this study, we used interferon-γ, in addition to puromycin aminonucleoside, and basic fibroblast growth factor, to be consistent with our previous work [26] and due to its potential contribution to podocyte injury [36]. We collected urine at day -2, day 7, and day 14 for 24 h using metabolic cages. On day 14, mice were euthanized and plasma, serum, kidneys, and liver were collected for analyte measurement and histologic analysis.

**Mouse urinary biomarkers and glomerular filtration rate (GFR)**

We determined urine albumin levels with Albuwell M ELISA kits (Ethos Biosciences, Newtown Square, PA). Urine creatinine concentrations were measured using the Creatinine Companion kit (Ethos Biosciences). Urine NGAL concentrations were measured using the Mouse Lipocalin-2/NGAL DuoSet ELISA (R&D Systems, Minneapolis, MN). We measured GFR ten days after puromycin aminonucleoside injection by monitoring the disappearance of
administered FITC-sinistrin (Medi Beacon, St. Louis, MO) with a fluorescence sensor (NIC-Kidney, Mannheim Pharma & Diagnostics, Mannheim, Germany). Fluorescent signals were analyzed according to the manufacturer’s instructions [37].

Analysis of mouse tissues
Chromogenic **in situ** detection of transgene RNA was performed on tissue microarrays prepared from formalin-fixed paraffin-embedded blocks, using RNAscope (Advanced Cell Diagnostics, Biotechnie, Minneapolis, MN), the RNA probe-Hs-APOL1-O1 (Advanced Cell Diagnostics), and the RNAscope 2.5 HD Reagent Kit [38]. For immunohistochemistry, tissues were fixed in 10% buffered formalin for 24 h, embedded in paraffin, and sectioned at 4–5 μm. After sectioning, the tissues were deparaffinized/rehydrated and antigens were retrieved with citrate-buffered medium in a hot water bath. APOL1 protein was detected with the primary antibody (5.17D12, rabbit monoclonal), which was kindly provided by Genentech (South San Francisco, CA), [11] the ImmPRESS HRP Universal Antibody (Horse Anti-Mouse/Rabbit IgG) Polymer Detection Kit, and the ImmPACT DAB EqV Peroxidase Substrate (Vector Laboratories, Burlingame, CA) protocol. Slides were counter-stained with hematoxylin. For histological analysis, tissues were stained with periodic acid-Schiff stain and evaluated by a nephropathologist (AZR). The percentage of sclerosed glomeruli (both segmentally and globally sclerosed) was determined for each mouse. A total of 72–367 glomeruli were evaluated per mouse. The number of injured tubules per area of renal cortex was also determined for each mouse. Podocyte density in individual glomeruli was determined by PodoCount, a computational tool for whole-slide podocyte quantification [39] after labeling for p57kip2, a marker of podocyte terminal differentiation (ab75974, Abcam, Cambridge, UK), detection with horse radish peroxidase (RU-HRP1000, Diagnostic BioSystems, Pleasanton, CA) and dianminobenzidine chromogen substrate (BSB0018A, Bio SB, Santa Barbara, CA), and post-staining with a periodic acid-Schiff stain without hematoxylin counterstain [40]. The method uses a combination of stain deconvolution [41], digital image processing [42, 43], and simple feature engineering [44, 45] to compute histologic morphometrics [46, 47] from glomeruli and resident podocyte nuclei in whole-slide images of kidney specimens.

Statistical analysis
Normality was assessed using the Shapiro-Wilk test and parameters were log-transformed when needed. The following parameters were log-transformed: concentrations of APOL1 in plasma and urine, eGFR, plasma cholesterol, plasma triglycerides, plasma HDL cholesterol, urine albumin-to-creatinine ratio, age, and body mass index. Medians were compared with the Wilcoxon test. Means were compared with the Student’s t-test. The Shapiro-Wilk tests, Wilcoxon test, Student’s t-tests, and linear regressions were performed within the R statistical environment (v4.0.0).

Study approval
SKS was approved by the Human Subjects Division at the University of Washington (#25422). All participants provided written informed consent. The analysis of the distributions of lipoprotein particles was performed at the Centers for Disease Control and was approved as research not involving identifiable human subjects. The mouse studies were performed at the National Institutes of Health in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved in advance by the NIDDK Animal Care and Use Committee (Animal study proposal, K097-KDB-17 & K096-KDB-20).
Results

Plasma concentrations of APOL1 are associated with race and eGFR, but not APOL1 genotype

Previous human studies have suggested that plasma concentrations of APOL1 are not associated with eGFR or chronic kidney disease [15, 30]. Since this contrasted with our previous observations that the amount of APOL1 in HDL is lower in participants with reduced eGFR, we developed an LC-MS/MS method to quantify the concentration of APOL1 in bulk plasma and determine the APOL1 genotype of subjects from SKS. Among the 465 participants who had samples available for analysis, 23.4% self-described their race as Black, 59.6% as White, and 17.0% as Other (Table B in S1 File). Similar to what was previously demonstrated [15], the plasma concentration of APOL1 in Black participants was significantly higher than in White participants [median (IQR): 370.7 nM (307.0–483.8) vs. 250.7 nM (200.4–314.5), P < 0.0001, Wilcoxon test; Table C in S1 File], which was independent of eGFR, urine albumin-to-creatinine ratio, and serum total protein concentration. In contrast to previous studies [15, 30], there was a weak correlation between eGFR and the APOL1 plasma concentration in the entire cohort (Fig 1A; r = 0.11; P = 0.013), which was also statistically significant in the subcohort of Black participants (N = 109, r = 0.22, P = 0.025). Importantly, the total concentration of APOL1 in plasma (i.e., the concentration of all isoforms) was not statistically different between Black participants with risk variant APOL1 and those with APOL1-G0 (Fig 1B).

Circulating risk variant APOL1 is biochemically different from APOL1-G0

In contrast to what was observed in bulk plasma, the relative amount of APOL1 in the HDL fraction of plasma was significantly lower in Black participants who carried risk variant APOL1 alleles compared with those who did not (Fig 1C), which suggested that most of the risk variant APOL1 resides in a different fraction of plasma, i.e., other than the HDL fraction (density = 1.063–1.210 g/mL) that is traditionally purified by density gradient ultracentrifugation. In participants who were heterozygous for risk variant APOL1, we demonstrated that APOL1-G0 peptide was under-recovered in the HDL fraction of plasma compared with bulk plasma (Fig 1D), which might suggest that risk variant APOL1 protein shifts APOL1-G0 protein to another fraction of plasma via heterodimer formation, but this is speculative. In support of this hypothesis, asymmetric flow field-flow fractionation demonstrated that APOL1 resided in larger particles in heterozygous individuals compared with homozygous APOL1-G0 participants (Fig 1E). Similar trends (lower concentrations of APOL1 protein in 9–11 nm diameter particles) were observed in the subgroup of Black participants, including those who were homozygous for risk variant APOL1 (Fig B in S1 File). The size of the larger particles appeared to be similar in size to apolipoprotein E-containing particles (Fig C in S1 File).

Urine concentrations of APOL1 are associated with plasma APOL1 concentrations and eGFR

The differences observed in the biochemical characteristics of polymorphic APOL1 in plasma raised the possibility of a dynamic process of APOL1 movement between particles and the possibility that APOL1 could be filtered into the urine (i.e., like albumin) and contribute to renal cell damage. To test this hypothesis, we determined the concentration of APOL1 in urine samples available from participants enrolled in SKS. The concentration of APOL1 in urine was significantly lower than in plasma (median [IQR], 49.9 [14.2–148.4] pM vs. 279.6 [217.1–352.0] nM, respectively). There was a modest positive correlation between plasma APOL1 concentration and urine APOL1 concentration (Table D in S1 File, r = 0.01, P = 0.03) and a weak
inverse correlation between urine APOL1 concentration and eGFR (Fig 1F, Table D in S1 File; \( r = -0.27; P < 0.001 \)), which was independent of self-described race and APOL1 genotype. In other univariate analyses, the amount of APOL1 in urine was positively correlated with plasma cholesterol field concentration and urine albumin-to-creatinine ratio (Table D in S1 File; \( r = 0.02, P = 0.003 \) and \( r = 0.22, P < 0.001 \), respectively). Importantly, in a multivariable model, the concentration of APOL1 in urine remained inversely correlated with eGFR, independent of urine albumin-to-creatinine ratio (Table D in S1 File, \( P < 0.001 \)). It should be noted that while there was a positive correlation between plasma APOL1 concentration and eGFR and a positive correlation between plasma APOL1 and urine APOL1 concentrations, there was a negative correlation between urine APOL1 concentration and eGFR. This is likely
explained by the weak correlation between urine and plasma APOL1 concentrations. Together, these data support a hypothesis in which circulating APOL1 enters the urine similar to albumin and may play a role in the development and progression of kidney disease. However, it is important to point out that these data are cross-sectional and repeated measures in the same human participants would be needed to further support the hypothesis that APOL1 protein enters the urine due to incident injury.

**Alb/APOL1 mice express APOL1 RNA in liver and human APOL1 protein circulates in plasma**

To more directly test the hypothesis that circulating APOL1 could exacerbate kidney injury, we developed a murine model that expresses APOL1 only in liver. By in situ hybridization, APOL1 RNA was detected in the livers of transgenic mice expressing APOL1-G0, APOL1-G1, or APOL1-G2 from an albumin promoter (Fig 2A). We confirmed that APOL1 was expressed in liver, but not in kidney or spleen (Fig D in S1 File). Human APOL1 protein was present in transgenic mouse plasma at concentrations near to or lower than those found in human plasma (10–130 vs. 87–732 nM, respectively), suggesting that the Alb/APOL1 mouse could be a suitable model to characterize the effects of plasma risk variant APOL1 protein in vivo (Fig 2B). The plasma concentration of APOL1 in Alb/APOL1-G1 mice was statistically higher than Alb/APOL1-G0 mice and similar with and without triple intervention (Fig E in S1 File).
Asymmetric flow field-flow fractionation demonstrated that the APOL1-G1 variant protein was preferentially carried on larger particles, as it is in human plasma, suggesting that the variant amino acid changes impart the different biochemical behavior of risk-variant APOL1 protein seen in human plasma (Fig 2C). The APOL1-G2 protein was shifted less substantially to larger particles.

Circulating risk variant APOL1 exacerbates kidney injury in a mouse model

As described in previous publications [26, 36], kidney injury was initiated in Alb/APOL1 transgenic mice using a triple intervention approach (interferon-γ, puromycin, and basic fibroblast growth factor), which targets the podocyte. In the absence of the triple intervention and kidney damage, APOL1 protein was not detected in glomeruli by immunohistochemistry; however, APOL1 protein was detected in the glomeruli of Alb/APOL1-G1 transgenic mice on day 14 of the intervention (Fig 3A). APOL1 protein appeared in the vascular lumen and within proximal tubular cells in Alb/APOL1-G1 mice, which may reflect non-specific uptake of APOL1 that has entered the tubular lumens. However, it was not clear from these images that APOL1 was present in the glomerular filtrate in Alb/APOL1 mice. After the triple intervention, there were pathological changes consistent with kidney damage (e.g., glomerular sclerosis, microcystic tubular dilatation, and tubular atrophy) (Fig 3B), which were significantly more common in the Alb/APOL1-G1 mice compared to Alb/APOL1-G0 mice and their littermate controls (Fig 4A and 4B). Kidney dysfunction, as assessed by reduced GFR and increased albuminuria, was present in Alb/APOL1-G1 mice after intervention (Fig 4C and 4D). Tubular injury, as measured by urinary NGAL, was most pronounced in Alb/APOL1-G1 mice (Fig 4E). Podocyte density was reduced in Alb/APOL1-G1 mice compared with Alb/APOL1-G0 and Alb/APOL1-G2 mice (Fig 5A). Further, the extent of podocyte loss in glomeruli correlated with albuminuria (Fig 5B). Taken together, data from this mouse model support the hypothesis that circulating risk variant APOL1 can exacerbate kidney injury in vivo.

Discussion

While we are unable to exclude an important role of podocyte-derived APOL1 in the progression of kidney injury, our data provide new evidence that liver-derived risk variant APOL1 circulating in plasma could contribute to the exacerbation of kidney injury in patients who are homozygous or compound heterozygous for risk variant alleles. The different biochemical properties of the risk variants, which lead to a shift of APOL1 protein out of the classically defined HDL fraction of plasma and into larger particles (Fig 1), complements previous studies demonstrating that risk variant APOL1 interacts with membranes and lipid droplets differently from APOL1-G0 [10, 25, 28, 31, 48]. These differences may explain the increased levels of endoplasmic reticulum stress [28], mitochondrial instability [27], and inflammasome activation [6, 25] that are observed in cell culture experiments using variant APOL1. The differences may also have important clinical implications with respect to the ability of APOL1 binding to the trypanosome serum resistance antigen protein (which inactivates APOL1-G0), to kill trypanosomes in vivo, or minimize symptoms in infected individuals [49–51]. The difference in particle size does not appear to be related to a shift of APOL1 protein between previously described trypanosome lytic factors (TLF1 and TLF2), because mice lack haptoglobin related protein, which is an important component of the TLFs [52].

Previous studies have demonstrated that plasma-derived APOL1 enters the urine under normal conditions [53]. Given the correlation of albumin and APOL1 concentrations in human urine (Table D in S1 File), the movement of APOL1 from plasma to urine may be
similar to that of albumin. Local inflammation and protein leakage through the glomerulus could theoretically provide a possible mechanism that could accentuate this process, giving plasma APOL1 better access to podocytes and proximal tubules (a speculative model is shown in Fig 6). In addition, urine provides an acidic environment, with luminal pH of 6.9 in the proximal tubule and 6.7 in the distal tubule [54]. This would favor plasma membrane insertion and lead to the formation of an active homotetrameric pore complex that could cause intracellular potassium loss, calcium influx, and cell lysis [21, 22, 28]. This cell death would be manifested as the observed human pathology of microcystic tubular dilatation and tubular atrophy [55]. Kidney diseases that are known to be associated with APOL1-driven pathology, including HIV-associated nephropathy, focal segmental glomerulosclerosis, and lupus nephritis, have been modeled in transgenic mice that express human APOL1 by several approaches [7, 56]. Cytokine-induced disruption of podocyte function, loss of glomerular basement membrane integrity, and reduced ability to retain

Fig 3. Circulating risk variant APOL1 and pathological changes. (A) Circulating APOL1 protein localizes to injured kidneys. To induce kidney damage and proteinuria in Alb/APOL1 mice (Alb-G0, Alb-G1, and Alb-G2) and their non-transgenic littermate controls (Lit. Cont.), mice received interferon-γ, puromycin, and basic fibroblast growth factor. Immunohistochemical detection of APOL1 protein in kidney from Alb/APOL1 mice after kidney-damaging intervention is shown compared with their littermate controls and non-treated control animals. Risk variant APOL1 protein localized to the kidney in Alb/APOL1-G1 mice and to a lesser extent in Alb/APOL1-G2 mice. Scale bars are 25 μm. (B) Circulating risk variant APOL1 is associated with pathological changes in the triple intervention model. Hematoxylin and eosin staining of kidney from Alb/APOL1 mice with and without the triple intervention demonstrated pathological differences in kidneys from treated mice that have circulating APOL1-G1 and APOL1-G2. Scale bars are 50 μm.

https://doi.org/10.1371/journal.pone.0276649.g003
proteins the size of APOL1, with its predicted molecular weight of 42 kDa, could be the prelude to injury of vulnerable cells by risk variant APOL1 in the glomerular filtrate, even in heterozygous individuals, as observed in patients with HIV-associated nephropathy [57].

Up to now, almost all mouse experiments have used models that express APOL1 in the podocyte [50, 58–60]. The results from the novel mouse model described here provide some support for the hypothesis that plasma APOL1, particularly APOL1-G1, could synergize with APOL1 protein expressed in podocytes to exacerbate renal injury. Although some pathological changes were also observed in the Alb/APOL1-G2 mice after the triple intervention, there were no measurable differences in glomerular sclerosis, tubular injury, GFR, or albuminuria. This finding, that Alb/APOL1-G1 mice manifested significant renal injury within two weeks while Alb/APOL1-G2 mice did not, suggests functional differences between APOL1-G1 and APOL1-G2 in plasma, as has been suggested previously [50, 61–64]. It may also be consistent with what is observed in human populations, in which APOL1-G1 associates with more significant albuminuria and kidney disease compared with APOL1-G2 in homozygous individuals [65–67], and with HIV-associated nephropathy and hypertension-associated end stage kidney disease in heterozygous individuals [57, 68]. However, it is also possible that longer observation might have been needed to observe changes in GFR or urine albumin-to-creatinine ratio in Alb/APOL1-G2 mice. Future studies might examine whether the effects of APOL1 variants in plasma extend to other mouse models of kidney injury and whether mouse plasma with APOL1 renal risk variants or purified APOL1 protein, when administered to other mice, can also induce kidney injury.

In addition to providing supporting evidence for a new, complementary mechanism to kidney disease progression, our results may also be important for the field of renal transplantation. Soon after the discovery that APOL1 polymorphisms account for a substantial fraction of the increased risk of kidney disease in people of sub-Saharan African descent [1, 2], there were reports that the APOL1 genotype of kidney donors [14], but not transplant recipients [13], was strongly associated with worse allograft outcomes and donated organs with two APOL1 risk variant alleles have shorter survival compared to organs with one or no risk variant alleles. These reports have been corroborated in several subsequent studies [12, 69–72] and there has been a proposal to incorporate genetic testing into kidney donation programs moving forward [73]. More recently, there have been two studies that have raised awareness of the potential role of recipient APOL1 genotype as well in transplant outcomes [16, 74, 75]. Our current findings in human plasma and human urine, which are correlative and hypothesis-generating, as
well as our data from APOL1 transgenic mice support a possible role for recipient APOL1 protein in the kidney disease process. The roles of donor and recipient genotypes are being prospectively investigated in the APOLLO study [76].
Limitations

While our study has notable strengths, including a large, well-characterized clinical cohort at various stages of chronic kidney disease, state-of-the-art methods to characterize lipoprotein particles in plasma, and a novel mouse model to evaluate the effects of circulating liver-derived APOL1 on disease progression, it has numerous limitations. First, the human data are cross-sectional and correlative and cannot be used to identify mechanisms or causality. As a result, these data instead lead to a compelling hypothesis that will need additional experiments, including mechanistic studies \textit{in vitro}, to gain a full understanding of the relationships that we have identified. Second, the concentrations of APOL1 circulating in mouse plasma were different for each APOL1 polymorphism, with Alb/APOL1-G1 mice having significantly higher concentrations of APOL1 than Alb/APOL1-G0 or Alb/APOL1-G2 mice. This complicates the comparison of findings between mice expressing APOL1 with different polymorphisms, particularly because the higher APOL1 concentrations in Alb/APOL1-G1 mice were associated with the higher levels of glomerulosclerosis, tubular injury, and albuminuria, as well as reduced eGFR. However, because the concentration of APOL1 in Alb/APOL1-G1 mice was generally lower than what is observed in humans, our data do support the hypothesis that circulating APOL1-G1 protein can exacerbate kidney injury, as evidenced by the comparison of Alb/APOL1-G1 mice with Alb/APOL1-G0 mice or their littermate controls. Third, the...
concentration of urine albumin in our mouse model was much higher than that observed in the human cohort, which suggests that the kidney injury in our mouse model was much more severe and thus less generalizable to human disease. Fourth, mice lack haptoglobin related protein, which is an important constituent in trypanosome lytic factor in humans, further limiting our ability to generalize our mouse model to human disease. Previous studies by the Raper laboratory have demonstrated that when haptoglobin related protein is expressed in mice along with APOL1, the resulting APOL1-containing lipoprotein particles are different than when APOL1 is expressed alone [77]. It would therefore be interesting to determine the effects of haptoglobin expression on our Alb/APOL1 model. Lastly, there is a possibility that the kidney damage observed in the Alb/APOL1-G1 transgenic mice could be due to insertional mutagenesis in an unrelated gene. However, since the tubular injury phenotype observed in our Alb/APOL1-G1 mouse model resembles that seen in human patients, we think it is more likely that the tubular injury is due to circulating APOL1.

Conclusions

Given these important limitations, our human and mouse studies are not conclusive. However, our data do support a hypothesis in which circulating APOL1 contributes to the renal dysfunction and pathology seen in humans. The leakage of APOL1 into urine, pore assembly in an acidic environment, and insertion into cell membranes could theoretically damage proximal tubules and contribute to the loss of kidney function. In addition, if plasma APOL1 plays a role in kidney disease, then it will be important to develop pharmaceuticals that prevent plasma and urine APOL1 multimerization.

Supporting information

S1 File.
(PDF)

Acknowledgments

We appreciate receiving BAC/APOL1 mice from Merck, Kenilworth, NJ. We appreciate receiving APOL1 antibodies from Genentech, South San Francisco, CA. We acknowledge Shashi Shrivastav, Huiyan Lu, Jonathan Street, Kris Ylaya, and Dominic Esposito for technical support, and Jurgen Heymann for critical manuscript review. The authors also thank the NIDDK Advanced Light Microscopy & Image Analysis Core (ALMIAC) for the use of its resources.

Author Contributions

Conceptualization: Michael Andrews, Teruhiko Yoshida, Ian H. de Boer, Tomas Vaisar, Jonathan Himmelfarb, Bryan Kestenbaum, Pinaki Sarder, Avi Z. Rosenberg, Jeffrey B. Kopp, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle.

Data curation: Michael Andrews, Clark M. Henderson, Hannah Pflaum, Ayako McGregor, Joshua A. Lieberman, Ian H. de Boer, Bryan Kestenbaum, Joon-Yong Chung, Stephen M. Hewitt, Briana A. Santo, Brandon Ginley, Pinaki Sarder, Andrew N. Hoofnagle.

Formal analysis: Michael Andrews, Clark M. Henderson, Joshua A. Lieberman, Ian H. de Boer, Bryan Kestenbaum, Stephen M. Hewitt, Briana A. Santo, Pinaki Sarder, Avi Z. Rosenberg, Jeffrey B. Kopp, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle.
**Funding acquisition:** Teruhiko Yoshida, Ian H. de Boer, Tomas Vaisar, Jonathan Himmelfarb, Bryan Kestenbaum, Pinaki Sarder, Jeffrey B. Kopp, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle.

**Investigation:** Michael Andrews, Teruhiko Yoshida, Clark M. Henderson, Hannah Pflaus, Ayako McGregor, Joshua A. Lieberman, Ian H. de Boer, Bryan Kestenbaum, Briana A. Santo, Brandon Ginley, Avi Z. Rosenberg, Taichi Murakami, Jeffrey B. Kopp, Andrew N. Hoofnagle.

**Methodology:** Teruhiko Yoshida, Clark M. Henderson, Hannah Pflaus, Joshua A. Lieberman, Bryan Kestenbaum, Joon-Yong Chung, Stephen M. Hewitt, Briana A. Santo, Brandon Ginley, Pinaki Sarder, Avi Z. Rosenberg, Taichi Murakami, Jeffrey B. Kopp, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle.

**Project administration:** Teruhiko Yoshida, Ian H. de Boer, Bryan Kestenbaum, Pinaki Sarder, Jeffrey B. Kopp, Andrew N. Hoofnagle.

**Resources:** Ian H. de Boer, Joon-Yong Chung, Stephen M. Hewitt, Taichi Murakami, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle.

**Software:** Briana A. Santo, Pinaki Sarder.

**Supervision:** Teruhiko Yoshida, Joshua A. Lieberman, Bryan Kestenbaum, Pinaki Sarder, Jeffrey B. Kopp, Andrew N. Hoofnagle.

**Validation:** Teruhiko Yoshida, Andrew N. Hoofnagle.

**Visualization:** Michael Andrews, Stephen M. Hewitt, Briana A. Santo, Brandon Ginley, Pinaki Sarder, Avi Z. Rosenberg, Zsuzsanna Kuklenyik.

**Writing – original draft:** Michael Andrews, Teruhiko Yoshida, Jeffrey B. Kopp, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle.

**Writing – review & editing:** Michael Andrews, Teruhiko Yoshida, Clark M. Henderson, Hannah Pflaus, Ayako McGregor, Joshua A. Lieberman, Ian H. de Boer, Tomas Vaisar, Jonathan Himmelfarb, Bryan Kestenbaum, Joon-Yong Chung, Briana A. Santo, Brandon Ginley, Pinaki Sarder, Avi Z. Rosenberg, Taichi Murakami, Jeffrey B. Kopp, Zsuzsanna Kuklenyik, Andrew N. Hoofnagle.

**References**

1. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. Science. 2010; 329(5993):841. https://doi.org/10.1126/science.1193032 PMID: 20647424

2. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011; 22(11):2129–37. https://doi.org/10.1681/ASN.2011040388 PMID: 21997394; PubMed Central PMCID: PMC3231787.

3. Pays E, Vanhollebeke B, Uzureau P, Lecordier L, Perez-Morga D. The molecular arms race between African trypanosomes and humans. Nature reviews Microbiology. 2014; 12(8):575–84. Epub 2014/07/01. https://doi.org/10.1038/nrmicro3298 PMID: 24975321.

4. Raper J, Friedman DJ. Parasitology: Molecular one-upmanship. Nature. 2013; 501(7467):322–3. https://doi.org/10.1038/501322a PMID: 24048062.

5. Siemens TA, Riella MC, Moraes TPd, Riella CV. APOL1 risk variants and kidney disease: what we know so far. J Bras Nefrol. 2018; 40(4):388–402. Epub 2018/07/26. https://doi.org/10.1590/2175-8239-JBN-2017-0033 PMID: 30052698.
6. Beckerman P, Bi-Karchin J, Park AS, Qiuc C, Dumner PD, Soomro I, et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med. 2017; 23(4):429–38. https://doi.org/10.1038/nm.4287 PMID: 28218918; PubMed Central PMCID: PMC5603285.

7. Bruggeman LA, Wu Z, Luo L, Madhavan S, Drawz PE, Thomas DB, et al. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy. PLoS One. 2019; 14(10):e0224408. https://doi.org/10.1371/journal.pone.0224408 PMID: 31661509; PubMed Central PMCID: PMC6818796 commercial use of APOL1 transgenic mice used in this study. This does not alter adherence to PLOS ONE policies on sharing data and materials.

8. Ekulu PM, Adebayo OC, Decuyperpe J, Bellucci L, Elnomor MA, Nkoy AB, et al. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype. J Am Soc Nephrol. 2020; 31(9):2065–82. https://doi.org/10.1681/ASN.2019080829 PMID: 32764138; PubMed Central PMCID: PMC7461681.

9. Ge M, Molina J, Ducasa GM, Mallella SK, Varona Santos J, Mitrofanova A, et al. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis. Hum Mol Genet. 2021; 30(3–4):182–97. https://doi.org/10.1093/hmg/ddab022 PMID: 33517446; PubMed Central PMCID: PMC8091039.

10. Gupta N, Wang X, Wen X, Moran P, Paluch M, Hass PE, et al. Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes. J Am Soc Nephrol. 2020; 31(9):2044–64. https://doi.org/10.1681/ASN.2019080829 PMID: 32764142; PubMed Central PMCID: PMC7461670.

11. Scales SJ, Gupta N, De Maziere AM, Posthuma G, Chiu CP, Pierce AA, et al. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes. J Am Soc Nephrol. 2020; 31(9):2044–64. https://doi.org/10.1681/ASN.2019080829 PMID: 32764142; PubMed Central PMCID: PMC7461670.

12. Freedman BJ, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant. 2015; 15(6):1615–22. https://doi.org/10.1111/ajt.13223 PMID: 25809272; PubMed Central PMCID: PMC4784684.

13. Lee BT, Kumar V, Williams TA, Abdi R, Bernhardy A, Dyer C, et al. The APOL1 Genotype of African American Kidney Transplant Recipients Does Not Impact 5-Year Allograft Survival. Am J Transplant. 2012; 12(7):1924–8. https://doi.org/10.1111/j.1600-6143.2012.04033.x PMID: 22487534.

14. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011; 11(5):1025–30. https://doi.org/10.1111/j.1600-6143.2010.03513.x PMID: 21486385; PubMed Central PMCID: PMC3083491.

15. Kozlitina J, Zhou H, Brown PN, Rohm RJ, Pan Y, Ayangou G, et al. Plasma levels of risk-variant APOL1 do not associate with renal disease in a population-based cohort. J Am Soc Nephrol. 2016; 27(10):3204–19. https://doi.org/10.1681/ASN.2015101121 PMID: 27005919.

16. Shetty AA, Tawhari I, Safar-Boueri L, Seif N, Alahmad A, Gargiulo R, et al. COVID-19-Associated Glomerular Disease. J Am Soc Nephrol. 2021; 32(1):33–40. https://doi.org/10.1681/ASN.2020060804 PMID: 33214201; PubMed Central PMCID: PMC7894674.

17. Sharma AK, Friedman DJ, Pollak MR, Alper SL. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1. The FEBS journal. 2016; 283(10):1846–62. Epub 2016/03/08. https://doi.org/10.1111/febs.13706 PMID: 26945671; PubMed Central PMCID: PMC4879057.

18. Sumaili EK, Shemer R, Kruzl-Davila E, Cohen EP, Mutantni PN, Bukabau JB, et al. G1 is the major APOL1 risk allele for hypertension-associated nephropathy in Central Africa. Clinical kidney journal. 2019; 12(2):188–95. Epub 2019/04/13. https://doi.org/10.1093/ckj/sfy073 PMID: 30976395; PubMed Central PMCID: PMC6452203.

19. Bruno J, Edwards JC. Kidney-disease-associated variants of Apolipoprotein L1 show gain of function in cation channel activity. The Journal of biological chemistry. 2021; 296:100238. https://doi.org/10.1074/jbc.RA120.019343 PMID: 33380423; PubMed Central PMCID: PMC7948812.

20. Giovinazzo JA, Thomson RP, Kalizova N, Zager PJ, Malani N, Rodriguez-Boulan E, et al. Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity. Elife. 2020;9. https://doi.org/10.7554/eLife.51185 PMID: 32427098; PubMed Central PMCID: PMC7292663.

21. Schaub C, Lee P, Racho-Jansen A, Giovinazzo J, Terra N, Raper J, et al. Coiled-coil binding of the leucine zipper domains of APOL1 is necessary for the open cation channel conformation. The Journal of biological chemistry. 2021:101009. https://doi.org/10.1016/j.jbc.2021.101009 PMID: 34331942; PubMed Central PMCID: PMC8446801.

22. Schaub C, Verdi J, Lee P, Terra N, Limon G, Raper J, et al. Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-lining residues within the C-terminal domain.
Circulating APOL1 in kidney disease

23. Muller D, Schmitz J, Fischer K, Granado D, Groh AC, Krausel V, et al. Evolution of renal-disease factor APOL1 results in cis and trans orientations at the endoplasmic reticulum that both show cytotoxic effects. Mol Biol Evol. 2021. https://doi.org/10.1093/molbev/msab220 PMID: 34323996.

24. Wen H, Kumar V, Lan X, Shoshfati SSM, Eng JM, Zhou X, et al. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress. Biosci Rep. 2018; 38(4). https://doi.org/10.1042/BSR20171713 PMID: 29967295; PubMed Central PMCID: PMC6131197.

25. Jha A, Kumar V, Haque S, Ayasolla K, Saha S, Lan X, et al. Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasome activation in APOL1 risk milieu. The FEBs journal. 2019. https://doi.org/10.1111/febs.15133 PMID: 31714001.

26. Okamoto K, Rausch JW, Wakashin H, Fu Y, Chung JY, Dummer PD, et al. APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R. Commun Biol. 2018; 1:188. Epub 2018/11/13. https://doi.org/10.1038/s42003-018-0188-2 PMID: 30417125; PubMed Central PMCID: PMC6220249.

27. Shah SS, Lannon H, Dias L, Zhang JY, Alper SL, Pollak MR, et al. APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore. J Am Soc Nephrol. 2019; 30(12):2355–68. https://doi.org/10.1681/ASN.2019020114 PMID: 31558683; PubMed Central PMCID: PMC6900802.

28. Chun J, Zhang JY, Wilkins MS, Subramanian B, Riella M, Granger JR, et al. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity. Proc Natl Acad Sci U S A. 2019; 116 (9):3712–21. https://doi.org/10.1073/pnas.1820411116 PMID: 30733285; PubMed Central PMCID: PMC6397558.

29. Rubinow KB, Henderson CM, Robinson-Cohen C, Himmelfarb J, de Boer IH, Vaisar T, et al. Kidney function is associated with an altered protein composition of high-density lipoprotein. Kidney Int. 2017; 92(6):1526–35. Epub 2017/07/30. https://doi.org/10.1016/j.kint.2017.05.020 PubMed Central PMCID: PMC5696089. PMID: 28754556.

30. Bruggeman LA, O'Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol. 2014; 25(3):634–44. https://doi.org/10.1681/ASN.2013070700 PMID: 24231663; PubMed Central PMCID: PMC3955593.

31. Weckerle A, Snipes JA, Cheng D, Gebre AK, Reisz JA, Murea M, et al. Characterization of circulating APOL1 protein complexes in African Americans. J Lipid Res. 2016; 57(1):120–30. https://doi.org/10.1194/jlr.M063453 PMID: 26586272; PubMed Central PMCID: PMC4693339.

32. Bosworth CR, Levin G, Robinson-Cohen C, Hoofnagel AN, Ruzinski J, Young B, et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int. 2012; 82(6):693–700. https://doi.org/10.1038/ki.2012.193 PMID: 22648296; PubMed Central PMCID: PMC3434313.

33. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737–49. https://doi.org/10.1056/NEJMoa2102953 PMID: 34554658; PubMed Central PMCID: PMC8822996.

34. Henderson CM, Lutsey PL, Miallak P, Laha TJ, Selvin E, Eckfeldt JH, et al. Measurement by a Novel LC-MS/MS Methodology Reveals Similar Serum Concentrations of Vitamin D-Binding Protein in Blacks and Whites. Clinical chemistry. 2016; 62(1):179–87. Epub 2015/10/11. https://doi.org/10.1373/clinchem.2015.244541 PMID: 26543697; PubMed Central PMCID: PMC4698095.

35. Norris Bradley M, Shuford CM, Holland PL, Levandoski M, Grant RP. Quality over quantity: A qualitative, targeted bottom-up proteomics approach to genotyping apolipoprotein L1. Clin Biochem. 2020; 82:58–65. https://doi.org/10.1016/j.clinbiochem.2020.03.015 PMID: 32234366.

36. Markowitz GS, Nshir SB, Stokes MB, D’Agati VD. Treatment with IFN- (alpha), - (beta), or - (gamma) is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5(4):607–15. https://doi.org/10.2215/CJN.07311009 PMID: 20203164; PubMed Central PMCID: PMC28492683.

37. Schreiber A, Shulhevich Y, Geraci S, Hesser J, Stsepanou D, Neudecker S, et al. Transcutaneous measurement of renal function in conscious mice. Am J Physiol Renal Physiol. 2012; 303(5):F783–8. Epub 2012/06/15. https://doi.org/10.1152/ajprenal.00279.2012 PMID: 22696603.

38. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005; 16(11):3306–14. Epub 2005/09/30. https://doi.org/10.1681/ASN.2004090804 PMID: 16192423.

39. Santo BA, Govind D, Daneshpajouhnejad P, Yang X, Wang XX, Myakala K, et al. PodoCount: A Robust, Fully Automated, Whole-Slide Podocyte Quantification Tool. Kidney Int Rep. 2022; 7(6):1377–92. https://doi.org/10.1016/j.ekir.2022.03.004 PMID: 35694561; PubMed Central PMCID: PMC9174049.

The Journal of biological chemistry. 2020; 295(38):13138–49. https://doi.org/10.1074/jbc.RA120.014201 PMID: 3272852; PubMed Central PMCID: PMC7504933.
40. Santo B, Rosenberg A, Sarder P. Automated Podocyte Quantification for Evaluation of Chronic Kidney Disease (1693). In “Abstracts from USCAP 2020: Medical Renal Pathology”. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2020; 33(Suppl 2):1741–73. Epub 2020/03/07. https://doi.org/10.1038/s41379-020-0479-2 PMID: 32139827; PubMed Central PMCID: PMC7104436.

41. Rufikro AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001; 23(4):291–9. PMID: 11531144.

42. Gonzales R, Wintz P. Digital image processing. Reading, Mass.: Addison-Wesley Publishing Co, Inc.; 1987.

43. Veta M, van Diest PJ, Koningsroor R, Huisman A, Viergever MA, Pluim JP. Automatic nuclei segmentation in H&E stained breast cancer histopathology images. PLoS One. 2013; 8(7):e70221. https://doi.org/10.1371/journal.pone.0070221 PMID: 23922958; PubMed Central PMCID: PMC3726421.

44. Ginley B, Lutnick B, Jen KY, Fogo AB, Jain S, Rosenberg A, et al. Computational Segmentation and Classification of Diabetic Glomerulosclerosis. J Am Soc Nephrol. 2019; 30(10):1953–67. https://doi.org/10.1681/ASN.2018121259 PMID: 31488606; PubMed Central PMCID: PMC6779352.

45. van der Walt S, Schonberger JL, Nunez-Iglesias J, Boulogne F, Warner JD, Yager N, et al. Scikit-image: image processing in Python. PeerJ. 2014; 2:e453. https://doi.org/10.7717/peerj.453 PMID: 25024921; PubMed Central PMCID: PMC4081273.

46. Kikuchi M, Wickman L, Hodgin JB, Wiggins RC. Podome trics as a Potential Clinical Tool for Glomerular Disease Management. Semin Nephrol. 2015; 35(3):245–55. https://doi.org/10.1016/j.semne phrol.2015.04.004 PMID: 24357669; PubMed Central PMCID: PMC4005315.

47. Venkatesdy M, Wang S, Yang Y, Patel S, Wickman L, Nishizono R, et al. Estimating podocyte number and density using a single histologic section. J Am Soc Nephrol. 2014; 25(5):1118–29. https://doi.org/10.1681/ASN.2013080859 PMID: 24357669; PubMed Central PMCID: PMC4005315.

48. Madhavan SM, O’Toole JF, Konieczkowski M, Barisoni L, Thomas DB, Ganesan S, et al. APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8. JCI Insight. 2017; 2(14). https://doi.org/10.1172/jci.insight.92581 PMID: 28724794; PubMed Central PMCID: PMC5518555.

49. Cooper A, Ilboudo H, Alibu VP, Ravel S, Enyaru J, Weir W, et al. APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. Elife. 2017; 6. https://doi.org/10.7554/eLife.25461 PMID: 28537557; PubMed Central PMCID: PMC5495568.

50. Friedman DJ, Pollak MR. APOL1 and Kidney Disease: From Genetics to Biology. Annu Rev Physiol. 2020; 82:323–42. Epub 2019/11/12. https://doi.org/10.1146/annurev-physi ol-021119-034345 PMID: 31710572.

51. Kabore JW, Ilboudo H, Noyes H, Camara O, Kabore J, Camara M, et al. Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea. PLoS Negl Trop Dis. 2017; 11(8):e0005833. https://doi.org/10.1371/journal.pntd.0005833 PMID: 28827791; PubMed Central PMCID: PMC5595334.

52. Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun. 1999; 67(4):1910–6. https://doi.org/10.1128/IAI.67.4.1910-1916.1999 PMID: 10085035; PubMed Central PMCID: PMC596545.

53. Althage M, Heinrich TM, Milliotis T, Bogstedt A, Ma L, Gautreaux MD, et al. Urine APOL1 Isoforms Reflect Plasma-Derived Liver-Synthesized Proteins. J Am Soc Nephrol. 2021. https://doi.org/10.1681/ASN.2020100341 PMID: 34162735.

54. Malnic G, De Mello Aires M, Giebisch G. Micropuncture study of renal tubular hydrogen ion transport in the rat. Am J Physiol. 1972; 222(1):147–58. https://doi.org/10.1152/ajplegacy.1972.222.1.147 PMID: 5060213.

55. Kopp JB, Rosenberg AZ. One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants. Adv Anat Pathol. 2019; 26(3):215–9. https://doi.org/10.1097/PAP.0000000000000221 PMID: 30624283; PubMed Central PMCID: PMC6458071.

56. Aghajan M, Botten SL, Althage M, Hart CE, Ericsson A, Maxwell I, et al. Antisense oligonucleotide treatment ameliorates IFN-gamma-induced proteinuria in APOL1-transgenic mice. JCI Insight. 2019; 4(12). Epub 2019/06/21. https://doi.org/10.1172/jci.insight.126124 PMID: 31217349; PubMed Central PMCID: PMC6629101.

57. Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, et al. APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. J Am Soc Nephrol. 2015; 26(11):2882–90. https://doi.org/10.1681/ASN.2014050469 PMID: 25788523; PubMed Central PMCID: PMC4625661.
58. Ma L, Divers J, Freedman BI. Mechanisms of Injury in APOL1-associated Kidney Disease. Transplantation. 2019; 103(3):487–92. https://doi.org/10.1097/TP.0000000000002509 PMID: 30371607; PubMed Central PMCID: PMC6226011.

59. Wu J, Raman A, Coffey NJ, Sheng X, Wahba J, Seassock MJ, et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest. 2021; 131(20). https://doi.org/10.1172/JCI136329 PMID: 34651582; PubMed Central PMCID: PMC8516463.

60. Yoshida T, Latt KZ, Heymann J, Kopp JB. Lessons From APOL1 Animal Models. Front Med (Lausanne). 2021; 8:762901. https://doi.org/10.3389/fmed.2021.762901 PMID: 34765626; PubMed Central PMCID: PMC8576052.

61. Bentley AR, Divers J, Shriner D, Doumatey AP, Gutierrez OM, Adeyemo AA, et al. APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans. BMC Genomics. 2015; 16:421. Epub 2015/05/31. https://doi.org/10.1186/s12864-015-1645-7 PMID: 26025194; PubMed Central PMCID: PMC4448293.

62. Gutierrez OM, Judd SE, Irvin MR, Zhi D, Limdi N, Palmer ND, et al. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. Nephrol Dial Transplant. 2016; 31(4):602–8. Epub 2015/07/15. https://doi.org/10.1093/ndt/gfv229 PMID: 26152403; PubMed Central PMCID: PMC4805128.

63. Freedman BI, Langefeld CD, Murea M, Ma L, Otvos JD, Turner J, et al. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant. 2011; 26(11):3805–10. Epub 2011/09/21. https://doi.org/10.1093/ndt/gfr542 PMID: 21931123; PubMed Central PMCID: PMC3203631.

64. Bentley AR, Doumatey AP, Chen G, Huang H, Zhou J, Shriner D, et al. Variation in APOL1 Contributes to Ancestry-Level Differences in HDLC-Kidney Function Association. Int J Nephrol. 2012; 2012:748984. Epub 2012/09/14. https://doi.org/10.1155/2012/748984 PMID: 22973631; PubMed Central PMCID: PMC4343781.

65. Brandenburg JT, Govender MA, Winkler CA, Boua PR, Agongo G, Fabian J, et al. Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations. Clin J Am Soc Nephrol. 2022; 17(6):798–808. https://doi.org/10.2215/CJN.14321121 PMID: 35577564; PubMed Central PMCID: PMC9269651.

66. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011; 22(11):2098–105. https://doi.org/10.1681/ASN.2011050519 PMID: 21997396; PubMed Central PMCID: PMC3231785.

67. Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res. 2014; 114(5):845–50. https://doi.org/10.1161/CIRCRESAHA.114.302347 PMID: 24379297; PubMed Central PMCID: PMC3982584.

68. Kanji Z, Powe CE, Wenger JB, Huang C, Ankers E, Sullivan DA, et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol. 2011; 22(11):2091–7. https://doi.org/10.1681/ASN.2010121234 PMID: 21997398; PubMed Central PMCID: PMC3231784.

69. Chang JH, Husain SA, Santoriello D, Stokes MB, Miles CD, Foster KW, et al. Donor's APOL1 Risk Genotype and "Second Hits" Associated With De Novo Collapsing Glomerulopathy in Deceased Donor Kidney Transplant Recipients: A Report of 5 Cases. Am J Kidney Dis. 2019; 73(1):134–9. https://doi.org/10.1053/j.ajkd.2018.05.008 PMID: 30054024; PubMed Central PMCID: PMC6309684.

70. Friedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, et al. APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation. 2016; 100(1):194–202. https://doi.org/10.1097/TP.0000000000000969 PMID: 26566060.

71. Mirza A, Kowalewska J, McCune T. Transplantation With APOL1 Risk Variant Kidney May Be Associated With Lifetime Risk for Recurrence of Focal Segmental Glomerulosclerosis: A Case Report and Review of Literature. Transplant Proc. 2019; 51(9):3077–9. https://doi.org/10.1016/j.transproceed.2019.04.056 PMID: 31324484.

72. Santoriello D, Husain SA, De Sarres SA, Bombach AS, Crew RJ, Vasilescu ER, et al. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Kidney Int. 2018; 94(6):1189–98. https://doi.org/10.1016/j.kint.2018.06.024 PMID: 30287079; PubMed Central PMCID: PMC6251748.

73. Gudsoorkar P, Anand M, Abu Jawdeh BG. APOL1 Genotyping in Potential African American Living Kidney Donors: Utility and Cost-Effectiveness. Am J Nephrol. 2020; 51(2):116–8. https://doi.org/10.1159/000505719 PMID: 31940609.

74. Friedman DJ. COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation. J Am Soc Nephrol. 2021; 32(1):1–2. https://doi.org/10.1681/ASN.2020111629 PMID: 33288631; PubMed Central PMCID: PMC7894672.
75. Zhang Z, Sun Z, Fu J, Lin Q, Banu K, Chauhan K, et al. Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. J Clin Invest. 2021. https://doi.org/10.1172/JCI146643 PMID: 34499625.

76. Freedman BI, Moxey-Mims MM, Alexander AA, Astor BC, Birdwell KA, Bowden DW, et al. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. Kidney Int Rep. 2020; 5(3):278–88. Epub 2020/03/11. https://doi.org/10.1016/j.ekir.2019.11.022 PMID: 32154449; PubMed Central PMCID: PMC7056919.

77. Molina-Portela MP, Samanovic M, Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J Exp Med. 2008; 205(8):1721–8. https://doi.org/10.1084/jem.20071463 PMID: 18606856; PubMed Central PMCID: PMC2525602.